Tirzepatide 10mg research peptide vial by FYH Peptides
Dual COA Verified
Metabolic Research Cat№ FYH-011

Tirzepatide

10mg • Lyophilized
$118.99 USD / vial

Synthetic 39-amino-acid peptide with dual receptor binding affinity at the GIP and GLP-1 receptors. Lyophilized form for in vitro endocrine and metabolic receptor research.

Technical Data

Catalog №
FYH-011
CAS №
2023788-19-2
Purity (HPLC)
99.93%
Mol. Weight
4813.45 g/mol
Mass / Vial
10mg
Form
Lyophilized
Tested Batch №
TZ-26TZ10-003
Storage
−20 °C, lyophilized
Origin
Switzerland, GMP-grade synthesis
Sequence / Structure
39-amino-acid dual GIP / GLP-1 receptor binding peptide

Certificate of Analysis

Tirzepatide 10mg HPLC Certificate of Analysis — batch TZ-26TZ10-003 Click image to open full-resolution COA →
Add to Inquiry

Published Research

Peer-reviewed literature indexed on NCBI PubMed referencing Tirzepatide. Listed for laboratory reference only — FYH Peptides makes no claim regarding the conclusions of any cited author. Click PubMed or DOI to read the original publication. Updated 2026-05-20.

  1. 1.
    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
    Aronne LJ, Sattar N, Horn DB, et al.
    JAMA · 2024
    PubMed DOI 10.1001/jama.2023.24945 PMID: 38078870
  2. 2.
    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP, Davies MJ, Rosenstock J, et al.
    The New England journal of medicine · 2021
    PubMed DOI 10.1056/NEJMoa2107519 PMID: 34170647
  3. 3.
    Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
    Nicholls SJ, Bhatt DL, Buse JB, et al.
    American heart journal · 2024
    PubMed DOI 10.1016/j.ahj.2023.09.007 PMID: 37758044
  4. 4.
    Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
    Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al.
    JAMA internal medicine · 2024
    PubMed DOI 10.1001/jamainternmed.2024.2525 PMID: 38976257
  5. 5.
    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    Loomba R, Hartman ML, Lawitz EJ, et al.
    The New England journal of medicine · 2024
    PubMed DOI 10.1056/NEJMoa2401943 PMID: 38856224
  6. 6.
    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
    Aronne LJ, Horn DB, le Roux CW, et al.
    The New England journal of medicine · 2025
    PubMed DOI 10.1056/NEJMoa2416394 PMID: 40353578
  7. 7.
    Tirzepatide: A Systematic Update.
    Forzano I, Varzideh F, Avvisato R, et al.
    International journal of molecular sciences · 2022
    PubMed DOI 10.3390/ijms232314631 PMID: 36498958
  8. 8.
    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J, Wysham C, Frías JP, et al.
    Lancet (London, England) · 2021
    PubMed DOI 10.1016/S0140-6736(21)01324-6 PMID: 34186022
⚠️ For Research Use Only. This product is sold exclusively for in vitro laboratory research use by qualified researchers and laboratories. It is NOT intended for human consumption, medical use, or as a dietary supplement. The FDA has not evaluated this product for safety or efficacy.
$118.99 USD / vial
Add to Inquiry